Assessment of cognitive scales to examine memory, executive function and language in individuals with down syndrome: Implications of a 6-month observational study

Xavier Liogier d’Ardhuy, Jamie O Edgin, Charles Bouis, Susana de Sola, Celia Goedner, Priya Kishnani, Jana Nöldeke, Sydney A Rice, Silvia Sacco, Lisa Squassante, Gail Spiridigliozzi, Jeannie Visootsak, James Heller, Omar Khwaja

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development) and adaptive behavior. Previous pharmacological studies in this population have been limited by a lack of appropriate endpoints that accurately measured change in cognitive and functional abilities. Therefore, the current longitudinal observational study assessed the suitability and reliability of existing cognitive scales to determine which tools would be the most effective in future interventional clinical studies. Subtests of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Cambridge Neuropsychological Test Automated Battery (CANTAB), and Clinical Evaluation of Language Fundamentals-Preschool-2 (CELF-P-2), and the Observer Memory Questionnaire-Parent Form (OMQ-PF), Behavior Rating Inventory of Executive Function®–Preschool Version (BRIEF-P) and Leiter International Performance Scale-Revised were assessed. The results reported here have contributed to the optimization of trial design and endpoint selection for the Phase 2 study of a new selective negative allosteric modulator of the GABAA receptor α5-subtype (Basmisanil), and can be applied to other studies in the DS population.

Original languageEnglish (US)
Article number300
JournalFrontiers in Behavioral Neuroscience
Volume9
Issue numberNOVEMBER
DOIs
StatePublished - Nov 18 2015

Fingerprint

Executive Function
Down Syndrome
Observational Studies
Language
Language Development
Aptitude
Neuropsychological Tests
Psychological Adaptation
GABA-A Receptors
Intellectual Disability
Population
Longitudinal Studies
Learning
Pharmacology
Equipment and Supplies

Keywords

  • Clinical trial
  • Cognition
  • Down syndrome
  • Language
  • Outcome measure

ASJC Scopus subject areas

  • Behavioral Neuroscience
  • Cognitive Neuroscience
  • Neuropsychology and Physiological Psychology

Cite this

Assessment of cognitive scales to examine memory, executive function and language in individuals with down syndrome : Implications of a 6-month observational study. / d’Ardhuy, Xavier Liogier; Edgin, Jamie O; Bouis, Charles; de Sola, Susana; Goedner, Celia; Kishnani, Priya; Nöldeke, Jana; Rice, Sydney A; Sacco, Silvia; Squassante, Lisa; Spiridigliozzi, Gail; Visootsak, Jeannie; Heller, James; Khwaja, Omar.

In: Frontiers in Behavioral Neuroscience, Vol. 9, No. NOVEMBER, 300, 18.11.2015.

Research output: Contribution to journalArticle

d’Ardhuy, XL, Edgin, JO, Bouis, C, de Sola, S, Goedner, C, Kishnani, P, Nöldeke, J, Rice, SA, Sacco, S, Squassante, L, Spiridigliozzi, G, Visootsak, J, Heller, J & Khwaja, O 2015, 'Assessment of cognitive scales to examine memory, executive function and language in individuals with down syndrome: Implications of a 6-month observational study', Frontiers in Behavioral Neuroscience, vol. 9, no. NOVEMBER, 300. https://doi.org/10.3389/fnbeh.2015.00300
d’Ardhuy, Xavier Liogier ; Edgin, Jamie O ; Bouis, Charles ; de Sola, Susana ; Goedner, Celia ; Kishnani, Priya ; Nöldeke, Jana ; Rice, Sydney A ; Sacco, Silvia ; Squassante, Lisa ; Spiridigliozzi, Gail ; Visootsak, Jeannie ; Heller, James ; Khwaja, Omar. / Assessment of cognitive scales to examine memory, executive function and language in individuals with down syndrome : Implications of a 6-month observational study. In: Frontiers in Behavioral Neuroscience. 2015 ; Vol. 9, No. NOVEMBER.
@article{64806fd04d794f0386b95f5ecdb8d3d7,
title = "Assessment of cognitive scales to examine memory, executive function and language in individuals with down syndrome: Implications of a 6-month observational study",
abstract = "Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development) and adaptive behavior. Previous pharmacological studies in this population have been limited by a lack of appropriate endpoints that accurately measured change in cognitive and functional abilities. Therefore, the current longitudinal observational study assessed the suitability and reliability of existing cognitive scales to determine which tools would be the most effective in future interventional clinical studies. Subtests of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Cambridge Neuropsychological Test Automated Battery (CANTAB), and Clinical Evaluation of Language Fundamentals-Preschool-2 (CELF-P-2), and the Observer Memory Questionnaire-Parent Form (OMQ-PF), Behavior Rating Inventory of Executive Function{\circledR}–Preschool Version (BRIEF-P) and Leiter International Performance Scale-Revised were assessed. The results reported here have contributed to the optimization of trial design and endpoint selection for the Phase 2 study of a new selective negative allosteric modulator of the GABAA receptor α5-subtype (Basmisanil), and can be applied to other studies in the DS population.",
keywords = "Clinical trial, Cognition, Down syndrome, Language, Outcome measure",
author = "d’Ardhuy, {Xavier Liogier} and Edgin, {Jamie O} and Charles Bouis and {de Sola}, Susana and Celia Goedner and Priya Kishnani and Jana N{\"o}ldeke and Rice, {Sydney A} and Silvia Sacco and Lisa Squassante and Gail Spiridigliozzi and Jeannie Visootsak and James Heller and Omar Khwaja",
year = "2015",
month = "11",
day = "18",
doi = "10.3389/fnbeh.2015.00300",
language = "English (US)",
volume = "9",
journal = "Frontiers in Behavioral Neuroscience",
issn = "1662-5153",
publisher = "Frontiers Research Foundation",
number = "NOVEMBER",

}

TY - JOUR

T1 - Assessment of cognitive scales to examine memory, executive function and language in individuals with down syndrome

T2 - Implications of a 6-month observational study

AU - d’Ardhuy, Xavier Liogier

AU - Edgin, Jamie O

AU - Bouis, Charles

AU - de Sola, Susana

AU - Goedner, Celia

AU - Kishnani, Priya

AU - Nöldeke, Jana

AU - Rice, Sydney A

AU - Sacco, Silvia

AU - Squassante, Lisa

AU - Spiridigliozzi, Gail

AU - Visootsak, Jeannie

AU - Heller, James

AU - Khwaja, Omar

PY - 2015/11/18

Y1 - 2015/11/18

N2 - Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development) and adaptive behavior. Previous pharmacological studies in this population have been limited by a lack of appropriate endpoints that accurately measured change in cognitive and functional abilities. Therefore, the current longitudinal observational study assessed the suitability and reliability of existing cognitive scales to determine which tools would be the most effective in future interventional clinical studies. Subtests of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Cambridge Neuropsychological Test Automated Battery (CANTAB), and Clinical Evaluation of Language Fundamentals-Preschool-2 (CELF-P-2), and the Observer Memory Questionnaire-Parent Form (OMQ-PF), Behavior Rating Inventory of Executive Function®–Preschool Version (BRIEF-P) and Leiter International Performance Scale-Revised were assessed. The results reported here have contributed to the optimization of trial design and endpoint selection for the Phase 2 study of a new selective negative allosteric modulator of the GABAA receptor α5-subtype (Basmisanil), and can be applied to other studies in the DS population.

AB - Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development) and adaptive behavior. Previous pharmacological studies in this population have been limited by a lack of appropriate endpoints that accurately measured change in cognitive and functional abilities. Therefore, the current longitudinal observational study assessed the suitability and reliability of existing cognitive scales to determine which tools would be the most effective in future interventional clinical studies. Subtests of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Cambridge Neuropsychological Test Automated Battery (CANTAB), and Clinical Evaluation of Language Fundamentals-Preschool-2 (CELF-P-2), and the Observer Memory Questionnaire-Parent Form (OMQ-PF), Behavior Rating Inventory of Executive Function®–Preschool Version (BRIEF-P) and Leiter International Performance Scale-Revised were assessed. The results reported here have contributed to the optimization of trial design and endpoint selection for the Phase 2 study of a new selective negative allosteric modulator of the GABAA receptor α5-subtype (Basmisanil), and can be applied to other studies in the DS population.

KW - Clinical trial

KW - Cognition

KW - Down syndrome

KW - Language

KW - Outcome measure

UR - http://www.scopus.com/inward/record.url?scp=84947716657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947716657&partnerID=8YFLogxK

U2 - 10.3389/fnbeh.2015.00300

DO - 10.3389/fnbeh.2015.00300

M3 - Article

AN - SCOPUS:84947716657

VL - 9

JO - Frontiers in Behavioral Neuroscience

JF - Frontiers in Behavioral Neuroscience

SN - 1662-5153

IS - NOVEMBER

M1 - 300

ER -